SCHEMBL28046

SCHEMBL28046

O=C1c2ccc(Cl)cc2C(=O)c2occc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.53
HSP90AA1 P07900 1/20 0.50
NQO1 P15559 1/20 0.47
POR P16435 1/20 0.47
PTPRC P08575 1/20 0.47
PPOX P50336 1/20 0.40
ITGA1 P56199 1/20 0.38
USP8 P40818 2/20 0.37
USP7 Q93009 2/20 0.37
USP47 Q96K76 1/20 0.37
CES1 P23141 2/20 0.37
TGM2 P21980 1/20 0.37
MAOB P27338 2/20 0.35
ESR1 P03372 1/20 0.35
MAOA P21397 1/20 0.35
UGT1A1 P22309 1/20 0.35
ESR2 Q92731 1/20 0.35
METAP1 P53582 1/20 0.35
PTPN1 P18031 1/20 0.35
RPS6KA3 P51812 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4229683 0.80 S100A4 (0.80) S100A4HSP90AA1PPOXITGA1USP8
SCHEMBL353693 0.80 S100A4 (0.80) S100A4HSP90AA1PPOXITGA1USP8
SCHEMBL16167323 0.79 NQO1 (0.47) NQO1PORPTPRCUSP8USP7
SCHEMBL29364602 0.77 PTPRC (0.76) S100A4NQO1PORPTPRCUSP8
SCHEMBL28782 0.77 PTPRC (0.76) S100A4NQO1PORPTPRCUSP8
SCHEMBL29581505 0.76 S100A4 (0.71) S100A4HSP90AA1PPOXITGA1USP8
SCHEMBL4319897 0.76 S100A4 (0.71) S100A4HSP90AA1PPOXITGA1USP8
SCHEMBL30345128 0.76 S100A4 (0.90) S100A4HSP90AA1PPOXITGA1USP8
SCHEMBL1133148 0.76 S100A4 (0.90) S100A4HSP90AA1PPOXITGA1USP8
SCHEMBL155593 0.74 S100A4 (0.87) S100A4HSP90AA1PTPRCPPOXITGA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871802-B2 Naphthoquinones for disease therapies ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) 2014-10-28 US disclosed
US-20130150437-A1 NAPHTHOQUINONES FOR DISEASE THERAPIES ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) 2013-06-13 US disclosed
WO-2012024818-A1 NOVEL ANPHTHOQUINONES FOR DISEASE THERAPIES ZHOUSHAN HAIZHONGZHOU XINSHENG PHARMACEUTICALS CO., LTD. (CN) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150437-A1 NAPHTHOQUINONES FOR DISEASE THERAPIES NQO1, NME2, CYP27B1 S100A4 2159/4885HSP90AA1 1319/4885NQO1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.